Skip to main content
AAN.com

Abstract

Objective:

While HIV-associated neurocognitive disorders (HAND) remain prevalent despite combination antiretroviral therapy (CART), the clinical relevance of asymptomatic neurocognitive impairment (ANI), the most common HAND diagnosis, remains unclear. We investigated whether HIV-infected persons with ANI were more likely than those who were neurocognitively normal (NCN) to experience a decline in everyday functioning (symptomatic decline).

Methods:

A total of 347 human participants from the CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) cohort were NCN (n = 226) or had ANI (n = 121) at baseline. Neurocognitive assessments occurred approximately every 6 months, with median (interquartile range) follow-up of 45.2 (28.7–63.7) months. Symptomatic decline was based on self-report (SR) or objective, performance-based (PB) problems in everyday functioning. Proportional hazards modeling was used to generate risk ratios for progression to symptomatic HAND after adjusting for baseline and time-dependent covariates, including CD4+ T-lymphocyte count (CD4), virologic suppression, CART, and mood.

Results:

The ANI group had a shorter time to symptomatic HAND than the NCN after adjusting for baseline predictors: adjusted risk ratios for symptomatic HAND were 2.0 (confidence interval [CI] 1.1–3.6; p = 0.02) for SR, 5.8 (CI 3.2–10.7; p < 0.0001) for PB, and 3.2 (CI 2.0–5.0; p < 0.0001) for either SR or PB. Current CD4 and depression were significant time-dependent covariates, but antiretroviral regimen, virologic suppression, and substance abuse or dependence were not.

Conclusions:

This longitudinal study demonstrates that ANI conveys a 2-fold to 6-fold increase in risk for earlier development of symptomatic HAND, supporting the prognostic value of the ANI diagnosis in clinical settings. Identifying those at highest risk for symptomatic decline may offer an opportunity to modify treatment to delay progression.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (2046.pdf)
File (coinvestigators.docx)
File (table_e-1.docx)
File (table_e-2.docx)

REFERENCES

1.
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789–1799.
2.
Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010;75:2087–2096.
3.
Sevigny JJ, Albert SM, McDermott MP, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol 2007;64:97–102.
4.
Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011;17:3–16.
5.
McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors: Multicenter AIDS Cohort Study. Neurology 1993;43:2245–2252.
6.
Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011;11:356.
7.
Torti C, Foca E, Cesana BM, Lescure FX. Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction? BMC Med 2011;9:138.
8.
Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002;59:1563–1567.
9.
Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders: HNRC Group: The HIV Neurobehavioral Research Center. Ann Neurol 1997;42:963–972.
10.
Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 2004;26:307–319.
11.
Wilkinson GS. The Wide Range Achievement Test, third edition, Wilmington, DE: Wide Range, Inc.; 1993.
12.
World Health Organization. Composite International Diagnostic Interview, version 2.1, Geneva: WHO; 1997.
13.
Beck AT, Steer RA, Brown GK. Beck Depression Inventory, second edition manual, San Antonio: The Psychological Corporation; 1996.
14.
Chelune GJ, Heaton RK, Lehman RA. Neuropsychological and personality correlates of patients complaints of disability. In:, Goldstein G, Tarter RE, eds. Advances in Clinical Neuropsychology, third edition. New York: Plenum Press; 1986: 95–126.
15.
Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004;10:317–331.
16.
Valpar International Corporation. Microcomputer Evaluation and Screening Assessment (MESA) Short Form 2. Tucson, AZ: Valpar International Corporation; 1986.
17.
Valpar International Corporation. Computerized Assessment (COMPASS). Tucson, AZ: Valpar International Corporation; 1992.
18.
Blackstone K, Moore DJ, Heaton RK, et al. Diagnosing symptomatic HIV-associated neurocognitive disorders: self-report versus performance-based assessment of everyday functioning. J Int Neuropsychol Soc 2012;18:79–88.
19.
Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 2004;26:759–778.
20.
Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65–70.
21.
Lentz MR, Kim WK, Lee V, et al. Changes in MRS neuronal markers and T cell phenotypes observed during early HIV infection. Neurology 2009;72:1465–1472.
22.
Ragin AB, Du H, Ochs R, et al. Structural brain alterations can be detected early in HIV infection. Neurology 2012;79:2328–2334.
23.
Sailasuta N, Ross W, Ananworanich J, et al. Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One 2012;7:e49272.
24.
Spudich SS, Ances BM. Central nervous system complications of HIV infection. Top Antivir Med 2011;19:48–57.
25.
Valcour V, Chalermchai T, Sailasuta N, et al. Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis 2012;206:275–282.
26.
Blackstone K, Iudicello JE, Morgan EE, et al. Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med 2013;7:255–263.
27.
Patton DE, Woods SP, Franklin D, et al. Relationship of Medication Management Test–Revised (MMT-R) performance to neuropsychological functioning and antiretroviral adherence in adults with HIV. AIDS Behav 2012;16:2286–2296.

Information & Authors

Information

Published In

Neurology®
Volume 82Number 23June 10, 2014
Pages: 2055-2062
PubMed: 24814848

Publication History

Received: October 29, 2013
Accepted: February 13, 2014
Published online: May 9, 2014
Published in print: June 10, 2014

Permissions

Request permissions for this article.

Disclosure

I. Grant receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH P01 DA12065, NIH U01 MH83506, NIH R01 MH78748, NIH R01 MH83552, NIH/University of Nebraska P01 DA026146, HHSN271201000030C, and HHSN271201000036C. He has also received honoraria from Abbott Pharmaceuticals as part of their Educational Speaker Program. D. Franklin receives support from HHSN271201000030C and HHSN271201000036C. R. Deutsch receives support from HHSN271201000036C, NIH P30 MH62512, and NIH P50 DA26306. S. Woods receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH R01 MH73419, NIH T32 DA031098, and NIH R01 MH084794. F. Vaida receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH R01 MH083552, NIH R01 AI47033, NIH U01 AI74521, NIH R01 MH085608, HHSN271201000030C, HHSN271201000036C, and Precision Photonics Corporation AI068543. Dr. Vaida has also served on a data safety and management board for Ardea Biosciences, Inc. R. Ellis received consultant fees from NeurogesX and is funded by NIH grants R01MH058076, U01MH83506, P30MH62512, R01MH83552, P50DA26306, R01MH095621, 2U01NS32228, and HHSN271201000036C. S. Letendre's salary is funded by NIH research awards, including HHSN271201000036C, R01 MH58076, R01 MH92225, P50 DA26306, and P30 MH62512. He has received support for research projects from Abbott, Merck, Tibotec, and GlaxoSmithKline. He has consulted for Gilead Sciences, GlaxoSmithKline, Merck, and Tibotec and has received lecture honoraria from Abbott and Boehringer-Ingelheim. T. Marcotte receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH HHSN271201000030C, NIH R01 MH83552, NIH R01 MH78748, and NIH R01 MH73433. J. Atkinson has received research support from NIH: P50 DA26306, U01 MH83506, HHSN271201000036C, HHSN271201000036C; coinvestigator; 2010-2015; Department of Veterans Affairs: NURA 01909-S, B4767-R; Principal Investigator, 2009-2015. A. Collier has ongoing research support from HHSN271201000036C, NIH UM1 AI069434, AI27757, AI057005, and R01 AI090783, current research support from Merck & Company, and past research support from Schering-Plough, Boehringer-Ingelheim, Gilead Sciences, Koronis, and Tibotec-Virco. She and an immediate family member previously owned stock in Abbott Laboratories, Bristol Myers Squibb, Johnson & Johnson, and Pfizer. C. Marra receives research support from the NIH (National Institute of Neurological Disorders and Stroke and NIMH). She receives royalties from Lippincott Williams & Wilkins and from UptoDate. D. Clifford is supported by NIH grants NS077384, AI69495, DA022137, HHSN271201000036C, NR012907, and the Alzheimer Association. He has also received research support from Lilly, Roche, Pfizer, Bavarian Nordic, and Biogen. In addition, Dr. Clifford has provided scientific advisory or consulting to Amgen, Biogen Idec, Drinker, Biddle and Reath (PML Consortium Scientific Advisory Board), Quintiles, Roche, Genentech, Novartis, GlaxoSmithKline, Millennium, Bristol Meyers Squibb, Genzyme, and Pfizer. B. Gelman receives support for NIH grants U24MH100930-01, R01NS079166, R01NS072005, 1R01MH101017, and HHSN271201000036C. J. McArthur receives support from HHSN271201000036C. S. Morgello reports no disclosures. D. Simpson receives research support from the NIH (National Institute of Neurological Disorders and Stroke and NIMH). He provided consultancy to GlaxoSmithKline and Gilead. J. McCutchan authors chapters on HIV for the Merck Manual and receives research funding related to NIH P30 MH62512, NIH U01 MH83506, NIH/Centers for Disease Control and Prevention (CDC) U2G PS00623, NIH U01 AI69432, HHSN271201000036C, NIH K30 RR22681, NIH R01 MH58076, and NIH U13 MH81676. I. Abramson receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH R01 MH61146, NIH HHSN271201000036C, NIH R01 DA21115, and NIH R21 MH78728. A. Gamst receives ongoing research support from NIH P30 MH62512, NIH P50 DA26306, NIH R01 HL95089, NIH U01 MH83506, NIH R01 HL84229, NIH R01 MH79752, NSF DBI-0446389, NIH HHSN271201000030C, and NIH U01 AG10483. C. Fennema-Notestine has received research support from the NIH (R21 NS069355, N01 MH22005, HHSN271201000036C, P30 MH062512, P50 DA026306, R01 MH079752, R01 AG031224, R01 AG022381, R01 MH084796, R01 MH042984-18S1, R01 MH092225-02S1) and from the Alzheimer's Association (IIRG-09-132430), and she serves as an Associate Editor for the Journal of Alzheimer's Disease (2012). D. Smith receives ongoing research support grants from the NIH: DA034978, MH62512, MH83552, MH097520, AI100665, and AI36214. R. Heaton receives ongoing research support from R01 MH92225, P50 DA26306, P30 MH62512, R01 MH60720, R01 MH58076, R01 MH78737, U01 MH83506, R01 MH83552, R01 MH80150, and HHSN271201000036C. Go to Neurology.org for full disclosures.

Study Funding

The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study is supported by awards N01 MH22005, HHSN271201000036C, and HHSN271201000030C from the NIH.

Authors

Affiliations & Disclosures

Igor Grant, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Abbott Pharmaceuticals speaker fee
Editorial Boards:
1.
(1)Journal of the International Neuropsychological Society, Associate Editor, 2002-2004, (2) Journal of Neurovirology, Associate Editor, 2002-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
Abbott Pharmaceuticals
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIDA, DA26306, PI, 2009-present, (2) NIMH, MH83506, PI, 2002-present, (3) NIA, AG15301, PI, 2002-present, (4) NIMH, HHSN271201000036C, PI, 2010-present, (5) NIMH, HHSN271201000030C, PI, 2010-present, (6) NIMH, MH62512, Co-I, 2011-present, (7) NIMH, MH78748, Co-I, 2007-present, (8) NIMH, MH83552, Co-I, 2008-present, (9) NIMH, MH094159, Co-I, 2011-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Donald R. Franklin, Jr, BS
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIMH N01 MH22005; HHSN271201000036C; HHSN271201000030C, Center Manager 2006-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Reena Deutsch, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) Palm Desert Historical Society, speaker honorarium (2) Oasis, lecturer payment
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
San Diego and Arizona Railway, The Impossible Railroad, Arcadia Publishing Company, 2011
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) TMARC, P50 DA026306, Statistician, 2012-2014 (2) HNRC, P30 MH062512, Statistician, 2012-2014 (3) CHARTER, N01 MH22005, Statistician, 2002-2004 (4) CHARTER Option period, N01 MH22005, Statistician, 2009-2010 (5) CHARTER Extension, HSN 271201000036C, Statistician, 2010-2014 (6) Remediation of HAND, R34 MH097567, Statistician, 2013-2014 (7) Long term effects of Chronic HIV infection on the developing brain, R01 MH094159, Statistician, 2012-2014
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Steven P. Woods, PsyD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Clinical and Experimental Neuropsychology, Editorial Board, 2012-present Archives of Clinical Neuropsychology, Associate Editor, 2011-present Neuropsychology, Editorial Board, 2013-present The Clinical Neuropsychologist, Editorial Board, 2011-present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
T32 DA31098 (Woods, Steven P.) 07/01/2011-06/30/2016 NIH Training in Research on Addictions in Interdisciplinary NeuroAIDS (TRAIN) The aim of this T32 is to train the next generation of academic clinical neuropsychologists in the science of substance use disorders and neuroAIDS. Role: Principal Investigator R01 MH73419 (Woods, Steven P.) 08/01/2013-07/31/2018 NIH Prospective Memory in HIV-1 Infection This renewal period takes a theoretically-driven approach towards improving HIV-associated prospective memory deficits among older adults in the laboratory and naturalistic settings in order to inform the development of novel, effective neurorehabilitation strategies for improving HAND and enhancing overall quality of life. Role: Principal Investigator R01 DA34497 (Naar-King, Sylvie/Woods, Steven P.) 08/01/2012-05/31/2017 NIH/Wayne State University Targeting PM to Improve HIV Adherence in Adolescents at Risk for Substance Abuse The primary aim of this subcontract is to examine the effectiveness of interventions based on prospective memory (PM) theory to improve medication adherence in youth living with HIV infection. Role: Co-Principal Investigator R01 MH84794 (Nichols, Sharon L.) 12/18/2009-11/30/2014 NIH Memory Functioning in Children and Adolescents with Perinatal HIV Infection To evaluate the effect of HIV infection acquired before or during birth on the ability of children and youth to learn and recall information, remember to perform future tasks, and manage their own attention and behavior. The study also will examine whether such problems affect medication adherence Role: Co-Investigator R21 MH98607 (Woods, Steven P.) 09/20/2012-08/31/2014 NIH A Web-Based Approach to Evaluating HIV-associated Neurocognitive Disorders To develop and validate a series of web-based tasks of everyday functioning (e.g., pharmacy refill, shopping, financial management) in persons living with HIV infection. Role: Principal Investigator P50 DA26306 (Grant, Igor) 09/30/2009-05/31/2014 NIH Translational Methamphetamine AIDS Research Center (TMARC) To provide scientific leadership, technical support, and opportunities for training to coalesce the efforts of an interdisciplinary group of investigators to elucidate METH/HIV-induced CNS injury. Role: Co-Investigator P30 MH62512 (Heaton, Robert K.) 04/01/2011-03/31/2016 NIH HIV Neurobehavioral Research Center (HNRC) A center that integrates and supports research into etiology, pathogenesis, phenomenology, treatment, and prevention of neuroAIDS. Role: Co-Investigator
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Florin Vaida, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Research Methodology Section Editor for the Californian Journal of Health Promotion Editor, ISRN-AIDS Frontiers in Genetics, Research Editor
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
(1) Statistical Consultant for Washington University in St Louis.
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH MH22005HIV, Investigator, 2006-2011 NIH MH083552, Investigator, 2008-2013 NIH MH62512, Investigator, 2007-2011 NIH AI074521, Investigator, 2007-2012 NIH MH085608, Investigator, 2009-2013 NIH MH58076, Investigator, 2008-2011
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ronald J. Ellis, MD, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NeurogesX, Inc. - Consultant fee for FDA Advisory panel
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH, P30 MH62512, Co-investigator, 2010-2015 (2) NIH, N01 HHSN271201000036C, Co-investigator, 2010-2015 (3) NIH, P50 DA26306, Co-investigator, 2009-2014 (4) NIH, R01 MH095621, Co-investigator, 2011-2016 (5) NIH, U01 MH83506, Co-investigator, 2008-2013 (6) NIH, R01 MH83552, Co-investigator, 2008-2013 (7) NIH, R01 MH085608, Co-investigator, 2009-2013 (8) NIH, R01 MH94159, Co-investigator, 2011-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
Abbott Laboratories, stock held by spouse Johnson and Johnson, stock held by spouse ABBVIE, stock held by spouse Merck and Co. Inc, stock held by spouse
Legal Proceedings:
1.
NONE
Scott L. Letendre, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
(1) ViiV Healthcare, 2013 (2) Abbvie, 2013
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Merck &Co., Inc., 2012
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) GlaxoSmithKline, Paid to the University of California (2) Merck & Co., Inc., Paid to the University of California (3) Abbvie, Paid to the University of California
Research Support, Government Entities:
1.
(1) NIH, U01 MH083506, consultant, 2012 (2) NIH, R01 MH58076, co-investigator, 2012 (3) NIH, P50 DA26306, co-investigator, 2012, 2013 (4) NIH, R01 MH73433, co-investigator, 2012 (5) NIH, N01 MH22005, co-investigator, 2012, 2013 (6) NIH, P30 MH62512, co-investigator, 2012, 2013 (7) NIH, R01 MH78748, co-investigator, 2012 (8) NIH, R21 MH85610, principal investigator, 2012 (9) NIH, R01, MH92225, principal investigator, 2012, 2013 (10) NIH, K24, MH097673, principal investigator, 2013
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Thomas D. Marcotte, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
International Neuropsychological Society (non-profit); honoraria
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
Neuropsychology of Everyday Functioning, Guilford Press, 2010
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIH, RO1 MH78748, Principal Investigator, 2007-12 (2) NIH, P30 MH62512, Co-investigator, 2011-16 (3) NIH, P50 DA26306, Co-investigator, 2009-14 (4) NIH, HHSN271201000036C, Co-Investigator, 2010-2015 (5) NIH, RO1 MH38552, Co-investigator, 2008-13 (6) NIH, RO1 MH94159, Co-Investigator 2011-2016 (7) NIH, R41 MH099964, Co-Investigator, 2013-2014 (8) NIH, R34 MH097567, Principal investigator, 2013-2016
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
J.H. Atkinson, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
National Institutes of Health: P50 DA26306, U01 MH83506 HHSN271201000036C, HHSN271201000036C; co-investigator; 2010-2015. Department of Veterans Affairs: NURA 01909-S, B4767-R; Principal Investigator, 2009-2015
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ann C. Collier, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
(1) Data and Safety Monitoring Board for Merck & Co.
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
(1) Schering-Plough - past research contract (2) Merck & Co.- past research contract
Research Support, Government Entities:
1.
(1) NIH/NIMH, N01 MH22005, Collier Co-PI on Subcontract, 3/12/03-8/31/15 (2) NIH/NIAID, UM1 AI 069481, Collier PI on Subcontract, 12/10/13 � 11/30/2020 (3) NIH/NIAID, UM1 AI 069434, Collier, PI, 1/1/07-5/30/14 (4) NIH/NIAID, P01 AI 057005, Collier, Core PI, 10/01/03-6/30/15 (5)NIH/NIMH, R01 NS082120, Collier Co-Investigator, 7/1/13-3/31/18 (6)NIH/NIAID, R01 AI090783, Collier, Co-Investigator, 6/1/10-5/31/14 (7)NIH/NIAID, UM1 AI068636, Co-Investigator, 6/1/13-1/31/14 (8)NIH/NINDS, RC1NS068904, Collier, Co-Investigator, 9/22/09-8/31/12 (9)NIH/NIAID, AI069918, Co-Investigator of Subcontract, 4/1/06-6/30/16 (10)Social and Scientific Systems (pass through funds from NIH), CRB-SSS-5-11-000930/CRB-DCR01-5-09-00291, Collier, PI on contract, 2/2/11-3/31/13 (11)Social and Scientific Systems, pass through funds from NIH, BRS-ACURE-S-11-00046-001329, Collier, PI of contract, 6/1/10-5/31/12
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
(1) Abbott, former stock owner, sold stock 8/23/12 (2) Bristo-Myers-Squibb, former stock owner, sold stock 8/23/12 (3) Johnson and Johnson, former stock owner, sold stock 8/23/12 (4) Pfizer, former stock owner, sold stock 8/23/12
Legal Proceedings:
1.
NONE
Christina M. Marra, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
I receive royalties from UpToDate for an article that I wrote on neurosyphilis. I receive royalties for a text entitled Infections of the Central Nervous System 3d ed, published by LWW in 2004.
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) NIH, NS34235, PI, 1996-2014; NIH, NS082120, PI, 2013-14; NIH, MH22005, Co-investigator, 2003-2014; NIH, AI094126, Co-investigator, 2012-2014; NIH, AI069434, Site Neurologist, 2007-2013; NIH, AI094122, Co-investigator, 2011-2013; NIH, NS32228, Co-investigator, 1997-2011; NIH, AI068636, PI on subcontract, 2011-2013
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David B. Clifford, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Amgen - PML Adjudication Board 2012 - Biogen Idec/Quintiles - DSMB for progressive MS trial 2011 - BMS - PML Adjudication Committee 2012 - Genentech PML Advisory Board regarding PML 2007 - 2014 Genzyme DSMB for CARE MS Study 2008-2011 Pfizer DMC for pregabalin neuropsthy study 2010 - 2011 Pfizer DMC for MAdCAM study 2011 - Millennium - Chair PML IAC for clinical trials 2009 - 2014 Millennium - ADCETRIS trial adjudication committee member 2012 - Genentech - PML Adjudication Committee (Chair) Etrolizumab trials 2014 - Sanofi - DMSB for MS trial 2014 -
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
Sun Pharmaceuticals - Speaker Honorarium - Symposium in Pune India (2013)
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Millennium Consulting regarding PML 2007-2014 Genzyme consultant 2009-2013 Biogen Idec scientific advisor regarding PML 2005-2014 IAS-USA speaker honorarium 2012 CMSC/ACTRIMS speaker honorarium 2012 ECTRIMS spearker honorarium 2012 Drinker, Biddle, Reath - Chair Scientific Advisory Committee of PML Consortium 2010 - Cytheris - PML trial design, FDA 2012 - 2013
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Lilly (DIAN - TU) 2013 - Roche (DIAN - TU) 2013 -
Research Support, Government Entities:
1.
NIH UO1 A169495 AIDS Clinical Trials Unit 2013-2020 NIH U10 NS077384 NeuroNEXT Trials Unit 2011- 2018 NIMH 22005 CHARTER Project (Washington U Site PI) 2007 - 2015 NIH R01 NR012907 (NINR,Ances - PI), Co-investigator, 2010- 2015 NIH R01 NR012907 (NINR, Ances - PI), Co-investigator, 2011-2016 DIAN TTU 12-243040 (Alzheimer Association, Bateman PI), Co-investigator, 2012-2016.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Arnold Todoro & Welch (legal consultation)2012 - Rainey, Kizer, Reviere, Bell (case review 2013 Silver and Deboskey PC (legal case review) 2013 Drinker Biddle and Reath LLC (PML Consortium Scientific Advisory Board) 2012 -
Benjamin B. Gelman, MD, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1) National Institute of Mental Health, U01MH083507, 2008-2010. 2) National Institute of Mental Health, R01MH079886, 2006-2010. 3) National Institute of Mental Health, N01MH022005, 2003-2010.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Justin C. McArthur, MBBS
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Relevare, scientific advisory board. 2006 - present. Stock options
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
Murphy JC, Szczepanowski RP, Schneider W, Meyer RA, McArthur JC, Polydefkis M. Device for thermal stimulation of small neural fibers. World Intellectual Property Organization,International Publication Number WO 03/040672 A2, 15 May 2003. Murinson BB, McArthur JC. Medical Device for Treatment of Ulnar Neuropathy. UlnarGuard � (JHU Ref: 4545) Nath A, Hoke A, McArthurJC. Immunophilin ligand treatment of antiretroviral toxic neuropathy (Provisional application number 60/466,650)
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
Biogen Idec 2009- (PI on clinical trial) Pfizer 2010 (PI on clinical trial)
Research Support, Government Entities:
1.
NIH research funding 1986 - present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Foundation for Peripheral Neuropathy research grant 2008- present
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Susan Morgello, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Not-for-profit; Advisory Board member, Temple University Comprehensive NeuroAIDS Center (CNAC)
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Neurovirology, editorial board, 2001 to present, no compensation received
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NIH: R24MH59724, U01MH083501, U24MH100931, PI, 1998-present R25MH080663, PI, 2007-present N01MH22005, Subsite PI, 2001-present
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
David M. Simpson, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Allergan,Depomed,Merz, Astellas, Ipsen, Syntaxin, Acorda, Viromed, Biogen
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
AIDS Patient Care (2008-current)
Patents:
1.
NONE
Publishing Royalties:
1.
Neuropathic Pain: Mechanisms, Diagonosis and Management; Oxford; 2012
Employment, Commercial Entity:
1.
Mount Sinai Medical Center
Consultancies:
1.
Allergan,Depomed,Merz, Astellas, Ipsen, Syntaxin, Acorda, Viromed, Biogen
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NeurogesX, Allergan, Merz, Ipsen, US Worldmeds, Astellas, Viromed, CSL Behring
Research Support, Government Entities:
1.
NINDS: R01-NS328-05-co-inv; R24 MH59724-co-inv;R01-NS-41198-co-inv; NIMH-00-AI-0005-co-PI
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
Peripheral neuropathy foundation
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
Proctor and Gamble: 2012-2014
John A. McCutchan, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Swiss Medical Journal
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
1 UO1 MH083506-01 (Grant, Igor) 06/05/2008-04/30/2013 0.96 Calendar National Institues of Health/NINDS $1,161,780 California NeuroAIDS Tissue Network (CNTN) � Project 1 UCSD Site Major Goals: A tissue bank comprised of CNS autopsy material from HIV-infected individuals who are well-characterized neuropsychologically and neuromedically. 5 U2G PS000623-03 (McCutchan, J. Allen) 09/30/2006-09/29/2011 2.88 Calendar National Institutes of Health $7,371,737 Centers for Disease Control and Prevention (CDC) PEPFAR Assistance Program for the Ethiopian Uniformed Services Major Goals: To assist colleagues in Ethiopia to treat HIV infection and build capacity for care and treatment. Subct #P010003906 (McCutchan, J. Allen) 4/14/2008 - 3/16/2009 0.96 Calendar U.S. Department of Defense (DOD)/SAIC $232,984 Develop a Medical and Clinical Curriculum for African Military Personnel Major Goals: Develop and implement flexible clinical and laboratory training programs in support of the prevention of HIV transmission and management of infected persons in sub-Saharan African military organizations. The currently targeted countries are Lesotho, South African, and Ethiopia. Develop programs in each country in collaboration with each military organization to meet its specific needs. N01 MH22005 (Grant, Igor) 09/01/2007 - 08/31/2010 1.80 Calendar National Institutes of Health $3,911,992 CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER)�Administrative Core/Neuromedical Core Major Goals: To assess the long-term effects of potent antiretroviral therapy on HIV-induced disease of the nervous system. 5 K30 RR022681-09 (Mehta, Ravindra) 09/30/2005 - 06/30/2010 1.80 Calendar National Institutes of Health $277,778 Clinical Research Enhancement Through Supplemental Training (CREST) Major Goals: Training in patient oriented research for clinical fellows at UCSD. 5 P30 MH62512-08 (Grant, Igor) 04/15/2006 - 03/31/2011 1.80 Calendar National Institutes of Health $1,372,898 HIV Neurobehavioral Research Center Major Goals: A center that integrates and supports research into etiology, pathogenesis, phenomenology, treatment, and prevention of neuroAIDS. 5 R01 MH58076-11 (Ellis, Ronald) 9/20/2006 - 7/31/2011 0.96 Calendar National Institutes of Health $944,402 HIV Neurocognitive Disorders: A Randomized Clinical Trial of CNS-targeted HAART Major Goals: Three integrated laboratory and clinical investigations that will examine the sources of CSF RNA, the potential role of the CNS reservoir for HIV, and how monitoring cerebrospinal fluid (CSF) viral load may guide antiretroviral therapy for the CNS. 5 UO1 AI069432-03 (Benson, Constance) 02/01/2007 � 11/30/2013 0.60 Calendar National Institutes of Health $2,859,435 UCSD Department of Medicine HIV/AIDS Clinical Trial Unit Major Goals: The UCSD Department of Medicine HIV/AIDS Clinical Trials Unit conducts investigator-initiated clinical trials of the NIH/NIAID Adult AIDS Clinical Trials Group (AACTG), intended to develop new or improve existing antiviral therapies or strategies for the treatment and prevention of HIV infection and its complications in adults and older adolescents infected with HIV. U13 MH81676 (McCutchan, J. Allen) 06/14/2007 - 04/30/2012 0.24 Calendar National Institutes of Health $8,205 International NeuroAIDS: Scientific and Methodological Research Challenges Major Goals: This will be a series of three meetings in the U.S. over five years to address scientific opportunities and perceived methodological hurdles to international neuroAIDS research in resource-limited settings.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Ian Abramson, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Associate editor - Journal of Nonparametric Statistics 2004-present - - No compensation
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
HNRC umbrella - to be completed shortly with help from the HNRC business office
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Anthony Gamst, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
NONE
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
NONE
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Christine Fennema-Notestine, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
NONE
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
Journal of Alzheimer's Disease, Associate Editor, 2012
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
IDEAA Consortium, UWM Site (NIDA grant 3R01DA030354-03S1)
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1) NIMH, HHSN271201000027C, Imaging Component PI, 2010-2015, (2) NIMH, P30-MH062512, Neuroimaging Core PI, 2011-2016, (3) NIA, R01-AG022381, Co-I, 2009-2014, (4) NIMH, R01-MH084796, Co-I, 2009-2014, (5) NIDA, P50-DA026306, Co-I, 2009-2014, (6) NINDS, R01-NS080655, Co-I, 2012-2016, (7) NIA, R01-AG031224, Co-I, 2008-2013, (8) NINDS, R21-NS069355, PI, 2009-2013, (9) NIMH, R01-MH092225-02S1, Co-I, 2011-2012, (10) NIMH, R01-MH042984-17A1, Co-I, 2010-2012
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Davey M. Smith, MD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
Pfizer Scientific Board for HIV medications 2008
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
editorial advisory board The Open AIDS Journal 2006 to present The Open Infectious Diseases Journal 2008 to present
Patents:
1.
NONE
Publishing Royalties:
1.
NONE
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
Consultant and Board Member--Symmunity LLC Consultant--Horologic and Testing Talent Services
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
ViiV Healthcare
Research Support, Government Entities:
1.
The investigator is supported by National Institutes of Health grants MH083552, AI077304, AI69432, MH62512, AI27670, AI38858, AI43638, AI43752, AI047745, UCSD Centers for AIDS Research Viral Pathogenesis Core (AI36214)and HIV Infection of the San Diego Veterans Affairs Healthcare System (10-92-035) from 2007 to present.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
Symmunity LLC
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
Robert K. Heaton, PhD
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.
Disclosure
Scientific Advisory Boards:
1.
(1) NINCDS, advisor, 2007-2010
Gifts:
1.
NONE
Funding for Travel or Speaker Honoraria:
1.
NONE
Editorial Boards:
1.
(1) Journal of the International Neuropsychological Society, editorial board, 2000-present, (2) Journal of Clinical and Experimental Neuropsychology, editorial board, 2000-present, (3) The Clinical Neuropsychologist, editorial board, 2000-present
Patents:
1.
NONE
Publishing Royalties:
1.
(1) Revised Comprehensive Norms for and Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults, Psychological Assessment Resources, Inc., 1991-present (2) Revised Comprehensive Norms for and Expanded Halstead-Reitan Battery: Demographically Adjusted Neuropsychological Norms for African American and Caucasian Adults Scoring Program, Psychological Assessment Resources, Inc., 1994-present (3) Wisconsin Card Sorting Test Manual-Revised and Expanded, Psychological Assessment Resources, Inc., 1991-present
Employment, Commercial Entity:
1.
NONE
Consultancies:
1.
NONE
Speakers' Bureaus:
1.
NONE
Other Activities:
1.
NONE
Clinical Procedures or Imaging Studies:
1.
NONE
Research Support, Commercial Entities:
1.
NONE
Research Support, Government Entities:
1.
(1)NIH P30 MH62512, Co-Investigator, 2006-2010, (2)NIH P50 DA26306, Co-Investigator, 2009-2010, (3) NIH P01 DA12065, Co-Investigator, 2005-2010, (4) NIH R01 MH60720, Co-Investigator, 2006-2010, (5) NIH R01 MH73433, Principal Investigator, 2005-2010, (6) NIH N01 MH22005, Co-Investigator, 2002-2010, (7) NIH R01 MH58076, Co-Investigator, 2006-2010, (8) NIH R01 MH78748,Co-Investigator, 2007-2010, (9) NIH R01 MH78737, Co-Investigator, 2007-2010, (10) NIH U01 MH83506, Co-Investigator, 2008-2010, (11) NIH R01 MH83552,Co-Investigator, 2008-2010, (12) NIH R01 MH81861, Co-Investigator, 2008-2010, (13) NIH P30MH062512-11, Principal Investigator, 2011-2016.
Research Support, Academic Entities:
1.
NONE
Research Support, Foundations and Societies:
1.
NONE
Stock/stock Options/board of Directors Compensation:
1.
NONE
License Fee Payments, Technology or Inventions:
1.
NONE
Royalty Payments, Technology or Inventions:
1.
NONE
Stock/stock Options, Research Sponsor:
1.
NONE
Stock/stock Options, Medical Equipment & Materials:
1.
NONE
Legal Proceedings:
1.
NONE
For the CHARTER Group
From the University of California (I.G., D.R.F., R.D., S.P.W., F.V., R.J.E., S.L.L., T.D.M., J.H.A., J.A.M., I.A., A.G., C.F.-N., D.M.S., R.K.H.), San Diego; the University of Washington (A.C.C., C.M.M.), Seattle; Washington University (D.B.C.), St. Louis, MO; University of Texas Medical Branch (B.B.G.), Galveston; Johns Hopkins University (J.C.M.), Baltimore, MD; and The Icahn School of Medicine at Mount Sinai (S.M., D.M.S.), New York, NY.

Notes

Correspondence to Dr. Grant: [email protected]
Coinvestigators are listed on the Neurology® Web site at Neurology.org.
The views expressed in this article are those of the authors and do not reflect the official policy or position of the United States Government.
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.

Author Contributions

Dr. Grant is the primary author on this manuscript and as such he was responsible for study conceptualization and design. All study data were available to him and he planned the statistical analyses and performed the interpretation of the results. Dr. Grant thereby assumes responsibility for the accuracy of the data, analysis, and interpretation. Donald R. Franklin is the CHARTER center manager and he provides integral coordination and dissemination of CHARTER data. Additionally, he contributed to this manuscript by assisting with study design, data analysis, drafting and revision of the manuscript. Dr. Deutsch contributed to all aspects of the manuscript, including study design, statistical analysis, and interpretation of results. Dr. Woods significantly contributed to all aspects of the manuscript, including study design, statistical analysis, and interpretation of results. He also strongly contributed in revising the manuscript. Dr. Vaida assisted with the interpretation of results along with drafting and revising the manuscript. Dr. Ellis made considerable contributions through management and coordination of the neuromedical data, and assisted with study design, analysis, and interpretation, as well as revisions to the manuscript. Dr. Letendre made considerable contributions through management and coordination of the laboratory data, and assisted with study design, analysis, and interpretation, as well as revisions to the manuscript. Dr. Marcotte assisted with the interpretation of results along with drafting and revising the manuscript. Dr. Collier assisted with primary data collection, drafting, and revising the manuscript. Dr. Marra assisted with primary data collection, drafting, and revising the manuscript. Dr. Clifford assisted with primary data collection, drafting, and revising the manuscript. Dr. Gelman assisted with primary data collection, drafting, and revising the manuscript. Dr. McArthur assisted with primary data collection, drafting, and revising the manuscript. Dr. Morgello assisted with primary data collection, drafting, and revising the manuscript. Dr. Simpson assisted with primary data collection, drafting, and revising the manuscript. Dr. McCutchan assisted with primary data collection, drafting, and revising the manuscript. Dr. Abramson assisted with drafting and revising the manuscript. Dr. Gamst assisted with drafting and revising the manuscript. Dr. Fennema-Notestine assisted with drafting and revising the manuscript. Dr. Smith assisted with drafting and revising the manuscript. Dr. Heaton significantly contributed to all aspects of the manuscript, including study design, statistical analysis, and interpretation of results. He also strongly contributed in revising the manuscript.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Cognitive Impairment in People Living with HIV and the Impact of Mood: Results from a Cross-Sectional Study, Journal of Clinical Medicine, 13, 6, (1631), (2024).https://doi.org/10.3390/jcm13061631
    Crossref
  2. Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture, Frontiers in Pharmacology, 15, (2024).https://doi.org/10.3389/fphar.2024.1369757
    Crossref
  3. HIV-associated neurocognitive disorder: key implications of the microbiota-gut-brain axis, Frontiers in Microbiology, 15, (2024).https://doi.org/10.3389/fmicb.2024.1428239
    Crossref
  4. Neurological Complications Caused by Human Immunodeficiency Virus (HIV) and Associated Opportunistic Co-infections: A Review on their Diagnosis and Therapeutic Insights, CNS & Neurological Disorders - Drug Targets, 23, 3, (284-305), (2024).https://doi.org/10.2174/1871527322666230330083708
    Crossref
  5. The prevalence of major depressive disorder in people with HIV : Results from the All of Us Research Program , HIV Medicine, 25, 8, (998-1004), (2024).https://doi.org/10.1111/hiv.13653
    Crossref
  6. Short‐term exposure to HIV Tat induces glial activation and changes in perineuronal nets, European Journal of Neuroscience, 60, 3, (4303-4316), (2024).https://doi.org/10.1111/ejn.16427
    Crossref
  7. Switching to Low Neurotoxic Antiretrovirals to Improve Neurocognition Among People Living With HIV-1-Associated Neurocognitive Disorder: The MARAND-X Randomized Clinical Trial, JAIDS Journal of Acquired Immune Deficiency Syndromes, 97, 2, (180-191), (2024).https://doi.org/10.1097/QAI.0000000000003480
    Crossref
  8. Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV, AIDS, 38, 14, (1932-1939), (2024).https://doi.org/10.1097/QAD.0000000000003989
    Crossref
  9. Association between tight junction proteins and cognitive performance in untreated persons with HIV, AIDS, 38, 9, (1292-1303), (2024).https://doi.org/10.1097/QAD.0000000000003923
    Crossref
  10. A 2-Year, Randomized, Clinical Trial Examining the Effects of Speed of Processing Cognitive Training on Quality-of-Life Indicators in Adults With HIV-Associated Neurocognitive Disorder in Birmingham, Alabama: Results of the Think Fast Study, Journal of the Association of Nurses in AIDS Care, 35, 2, (104-121), (2024).https://doi.org/10.1097/JNC.0000000000000449
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share